Medical Aesthetics Company Evolus Soars on Strong Q4 Report and Guidance
Evolus, a medical aesthetics company, made a significant comeback on Tuesday, reclaiming its 50-day and 200-day moving averages after a strong preliminary fourth-quarter report and guidance for 2025. The company’s shares surged 28.3% to $13.48, reaching their highest point since early November.
Beating Expectations
Evolus preannounced $79 million in fourth-quarter sales, a 30% increase from the year-earlier period and above forecasts of $76 million to $77 million. This impressive performance helped the company surpass its 2024 outlook, which had been lowered by 1% in November, leading to a 15% stock dive.
Analysts Weigh In
Leerink Partners analyst Marc Goodman praised the company’s announcement, stating that it likely made investors feel much better after the November setback. “We really liked the stock at $17 back in November, so we like it even more today at $13-$14 with this kind of announcement,” Goodman said.
Guidance for 2025
Evolus guided to $345 million to $355 million in sales for 2025, bracketing the Street’s view for $352 million, according to Mizuho Securities analyst Uy Ear. The company also expects the Food and Drug Administration to approve its Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels in the second quarter.
Expanding Product Line
These gels, which help reduce the appearance of fine lines and wrinkles, are expected to generate 8% to 10% of 2025 sales. The expected approval will transition Evolus from a single-product company to a “multiproduct innovator,” according to Chief Executive David Moatazedi.
Competition in the Market
Evolus’ flagship product, Jeuveau, a neurotoxin filler, competes with AbbVie’s Botox, the market leader. While Botox is projected to bring in $761 million in fourth-quarter sales, Jeuveau is growing quickly, with sales rising 22% to 42% over the past four quarters.
A Brighter Future Ahead
With its strong Q4 report and guidance for 2025, Evolus is poised for a promising future. As the company expands its product line and continues to grow, investors may want to take notice of this medical aesthetics company on the rise.
Leave a Reply